Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma.
about
Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE.Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinomaCarbogen gas-challenge blood oxygen level-dependent magnetic resonance imaging in hepatocellular carcinoma: Initial results.Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolizationUnresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteriaSurvival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control.Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies.Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt.Objective Measurement of Arterial Flow Before and After Transcatheter Arterial Chemoembolization: A Feasibility Study Using Quantitative Color-Coding Analysis.Quantitative assessment of angiographic perfusion reduction using color-coded digital subtraction angiography during transarterial chemoembolization.Quantitative Real-Time Fluoroscopy Analysis on Measurement of the Hepatic Arterial Flow During Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Comparison with Quantitative Digital Subtraction Angiography Analysis.Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma.
P2860
Q33620645-5A2AE9FE-8970-48AB-9AA7-458AE22F9D44Q34681150-3CB8929F-8A33-4BCE-B022-A51A139F69AAQ36085650-B7D1A595-ED6B-4A23-9655-0FFA62420FE2Q36272834-65C2132C-1773-4D97-93C9-1CB59FC11521Q37039550-6D706A50-F601-4CEA-9308-EB98F28DC15CQ37432022-699FBB6F-D202-4E2C-A424-F5B9094850E5Q37695686-642202D2-539E-41C9-8380-EE4990E1C441Q39025146-4DDC606C-2BC1-44CC-84A3-329BC561E360Q40279283-61DD89BB-1E2E-4204-8FF4-A1D96CD763B8Q40363852-1A5D1862-B996-4ECC-922E-1348C4F59666Q40394906-DA873444-CFF2-4041-AF34-F831F2EE14AEQ41592391-60C243AE-5714-4AA6-B951-635853E57DFE
P2860
Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chemoembolization endpoints: e ...... with hepatocellular carcinoma.
@ast
Chemoembolization endpoints: e ...... with hepatocellular carcinoma.
@en
type
label
Chemoembolization endpoints: e ...... with hepatocellular carcinoma.
@ast
Chemoembolization endpoints: e ...... with hepatocellular carcinoma.
@en
prefLabel
Chemoembolization endpoints: e ...... with hepatocellular carcinoma.
@ast
Chemoembolization endpoints: e ...... with hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Chemoembolization endpoints: e ...... with hepatocellular carcinoma
@en
P2093
Andrew C Larson
Dingxin Wang
Kent T Sato
Reed A Omary
Robert J Lewandowski
Robert K Ryu
P2860
P304
P356
10.2214/AJR.10.4770
P407
P577
2011-04-01T00:00:00Z